Literature DB >> 8697052

Dopamine receptor subtype agonists and feeding behavior.

P Terry1, D B Gilbert, S J Cooper.   

Abstract

Stimulation or blockade of various dopamine receptor subtypes is associated with reduced feeding. For example, D2 receptor agonists suppress feeding in food-deprived and free-feeding rats, and in rats given access to a highly palatable diet. Similarly, reduced food intake is associated with the actions of diverse D1 receptor agonists, and these compounds can interact synergistically with D2 receptor agonists to potentiate reductions in feeding. Using microstructural analysis to compare D1 and D2 agonist effects, specific differences emerge in their modes of action. D1 agonists reduce the duration of feeding, primarily by decreasing the frequency of feeding bouts, whereas D2 agonists reduce the local rate of eating. However, since D1 agonists uniquely reduce feeding in the absence of other behavioral impairments and are less disruptive of the pattern of feeding behavior, it has been suggested that D1 agonists are more likely than D2 agonists to act on central mechanisms regulating food intake. Moreover, only D1 agonists are effective in suppressing sucrose sham-feeding, suggesting that D1 receptor stimulation may promote satiety. Nevertheless, many questions remain. For example, antagonist studies have implicated 5-HT receptor stimulation in the anorectic effects of D1 agonists, suggesting that further pharmacological and behavioral analyses of receptor-subtype agonist effects are required. Above all, recent developments in the classification of dopamine receptor subtypes reveal the need for new studies examining the involvement of D3, D4 and D5 receptors in feeding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8697052     DOI: 10.1002/j.1550-8528.1995.tb00221.x

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  16 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Intensely pleasurable responses to music correlate with activity in brain regions implicated in reward and emotion.

Authors:  A J Blood; R J Zatorre
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

3.  Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.

Authors:  C D Gibson; W Karmally; D J McMahon; S L Wardlaw; J Korner
Journal:  Diabetes Obes Metab       Date:  2011-12-27       Impact factor: 6.577

Review 4.  Food reinforcement and eating: a multilevel analysis.

Authors:  Leonard H Epstein; John J Leddy; Jennifer L Temple; Myles S Faith
Journal:  Psychol Bull       Date:  2007-09       Impact factor: 17.737

5.  Prefrontal systems involvement in binge eating.

Authors:  A G Boeka; K L Lokken
Journal:  Eat Weight Disord       Date:  2011-06       Impact factor: 4.652

Review 6.  You are what you eat: influence of type and amount of food consumed on central dopamine systems and the behavioral effects of direct- and indirect-acting dopamine receptor agonists.

Authors:  Michelle G Baladi; Lynette C Daws; Charles P France
Journal:  Neuropharmacology       Date:  2012-02-23       Impact factor: 5.250

7.  Chronic administration of the dopamine D2/3 agonist ropinirole invigorates performance of a rodent slot machine task, potentially indicative of less distractible or compulsive-like gambling behaviour.

Authors:  Paul J Cocker; M Tremblay; S Kaur; Catharine A Winstanley
Journal:  Psychopharmacology (Berl)       Date:  2016-10-06       Impact factor: 4.530

8.  DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia.

Authors:  Todd Lencz; Delbert G Robinson; Barbara Napolitano; Serge Sevy; John M Kane; David Goldman; Anil K Malhotra
Journal:  Pharmacogenet Genomics       Date:  2010-09       Impact factor: 2.089

9.  A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.

Authors:  Stephen M. Stahl; James F. Pradko; Barbara R. Haight; Jack G. Modell; Carol B. Rockett; Susan Learned-Coughlin
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

10.  Transcription factors FOXA1 and FOXA2 maintain dopaminergic neuronal properties and control feeding behavior in adult mice.

Authors:  Alessandro Pristerà; Wei Lin; Anna-Kristin Kaufmann; Katherine R Brimblecombe; Sarah Threlfell; Paul D Dodson; Peter J Magill; Cathy Fernandes; Stephanie J Cragg; Siew-Lan Ang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.